The American Journal of Medicine
Volume 122, Issue 4 , Pages 374-379 , April 2009

Aspirin Use and Risk of Type 2 Diabetes in Apparently Healthy Men

  • Yasuaki Hayashino, MD, DMSc, MPH

      Affiliations

    • Department of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine, Kyoto, Japan
    • Corresponding Author InformationRequests for reprints should be addressed to Yasuaki Hayashino, MD, DMSc, PMH, Kyoto University Graduate School of Medicine, Department of Epidemiology and Healthcare Research, Yoshida-konoe-cho, Sakyo-ku, Kyoto, Japan 606-8501
    • ,
  • Charles H. Hennekens, MD, DrPH

      Affiliations

    • Departments of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Miami, Fla
    • Department of Clinical Science and Medical Education and Center of Excellence, Florida Atlantic University, Boca Raton
    • ,
  • Tobias Kurth, MD, ScD

      Affiliations

    • Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Department of Epidemiology, Harvard School of Public Health, Boston, Mass

References 

  1. Nilsson PM, Roost M, Engstrom G, et al. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care. 2004;27:2464–2469
  2. Type 2 Diabetes Complications. http://www.diabetes.org/type-2-diabetes/complications.jsp2004;Accessed December 22, 2004.
  3. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 2004;27(Suppl 1):S72–S73
  4. Ebstein W. Zur therapie des diabetes mellitus insbesondere uber die anwedung des salicylsauren natron bei demselben. Berl Klin Wochenschr. 1876;13:337–340
  5. Williamson RT, Loud MD. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J. 1901;1:760
  6. Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. Br Med J. 1957;2:1071
  7. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321–1326
  8. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhausl WK. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia. 1985;28:671–676
  9. Giugliano D, Sacca L, Scognamiglio G, et al. Influence of acetylsalicylic acid on glucose turnover in normal man. Diabetes Metab. 1982;8:279–282
  10. Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab. 1983;57:1102–1106
  11. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  12. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204
  13. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur Heart J. 2002;23:831–834
  14. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation. 2004;109:1729–1734
  15. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–1677
  16. Ismail N, Neyra R, Hakim R. The medical and economical advantages of early referral of chronic renal failure patients to renal specialists. Nephrol Dial Transplant. 1998;13:246–250
  17. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1988;318:262–264
  18. Final report on the aspirin component of the ongoing Physicians' Health Study (Steering Committee of the Physicians' Health Study Research Group). N Engl J Med. 1989;321:129–135
  19. Manson JE, Buring JE, Satterfield S, Hennekens CH. Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians. Am J Prev Med. 1991;7:150–154
  20. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–1149
  21. Sturmer T, Buring JE, Lee IM, et al. Colorectal cancer after start of nonsteroidal anti-inflammatory drug use. Am J Med. 2006;119:494–502
  22. Gilgore SG. The influence of salicylate on hyperglycemia. Diabetes. 1960;9:392
  23. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77–80
  24. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–959
  25. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851–860
  26. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  27. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  28. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  29. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157–160
  30. Harris MI. Prevalence of noninsulin-dependent diabetes and impaired glucose tolerance, in National Diabetes Data Group: Diabetes in America. USDHHS, NIH; 1985;Report No.: pub no 85-1468
  31. Pradhan AD, Cook NR, Manson JE, et al. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care. 2009;32:3–8

 Funding: The Physicians Health Study was supported by grants CA-34944, CA-40360, and CA-097193 from the National Cancer Institute and grants HL-26490 and HL-34595 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. The study sponsors were not involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.

 Conflict of Interest: Dr Hayashino has nothing to disclose. Dr Hennekens is funded by the Charles E. Schmidt College of Biomedical Science, Department of Clinical Science and Medical Education and Center of Excellence at Florida Atlantic University (FAU) as Principal Investigator on 2 investigator-initiated research grants funded to FAU by Bayer testing the effects of aspirin dose on platelet biomarkers, inflammatory markers, nitric oxide formation, and endothelial function; he serves as an independent scientist in an advisory role to investigators and sponsors, including as Chair or Member on Data and Safety Monitoring Boards, for Actelion, Amgen, AstraZeneca, Bayer, Biovail, Bristol-Myers Squibb, Chattem, Dainippon Sumitomo, Delaco, Dechert, Food and Drug Administration, GlaxoSmithKline, Keryx, Lilly, McNeil, Merck, National Association for Continuing Education, National Institutes of Health, Novartis, Pfizer, PriMed, Reliant, Sanofi-Aventis, Sidley Austin, Solvay, TAP, United BioSource Corporation, UpToDate and Wyeth; he serves on speakers bureaus for the International Atherosclerosis Society, AstraZeneca concerning lipids and heart failure, as well as Bristol-Myers Squibb, Reliant, and Pfizer concerning lipids; he receives royalties for authorship or editorship of 3 textbooks; he receives royalties as co-inventor on patents concerning inflammatory markers and cardiovascular disease which are held by Brigham and Women's Hospital; he has an investment management relationship with SunTrust Bank who has sole discretionary investment authority. Dr Kurth has received within the last 5 years investigator-initiated research funding as Principal or Co-Investigator from the National Institutes of Health, Bayer AG, McNeil Consumer and Specialty Pharmaceuticals, Merck, and Wyeth Consumer Healthcare; he is a consultant to i3 Drug Safety and WHISCON; he received an honorarium from Organon for contributing to an expert panel and from Genzyme and Pfizer for educational lectures.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)01105-4

doi: 10.1016/j.amjmed.2008.09.044

The American Journal of Medicine
Volume 122, Issue 4 , Pages 374-379 , April 2009

Article Tools